In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2791-2802

  Saarinen, U M ^a   Wikstrom S ^a   Makipernaa A ^a   Lanning, M ^a   Perkkio M ^a   Hovi, L ^a   Rapola, J ^a   Sariola, H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; NEUROBLASTOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

EID: 0029738122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2791     Document Type: Article

References (55)

1. Matthay KK: Neuroblastoma, in Pochedly C (ed): Neoplastic Diseases of Childhood. Chur, Switzerland, Harwood Academic, 1994, pp 735-778
2. Cheung NKV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
3. Pritchard J, McElvain TJ, Graham-Pole J: High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 45:86-94, 1982
4. August CS, Serota FT, Koch PA, et al: Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous marrow reconstitution. J Clin Oncol 2:609-616, 1984
5. Hartmann O, Kalifa C, Benhamou E, et al: Treatment of advanced neuroblastoma with high dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 16:165-169, 1986
6. Hartmann O, Benhamou E, Beaujean F, et al: Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 5:1205-1211, 1987
7. Philip T, Bernard JL, Zucker JM, et al: High-dose chemoradio-therapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over 1 year of age. J Clin Oncol 5:266-271, 1987
8. Dini G, Philip T, Hartmann O, et al: Bone marrow transplantation for neuroblastoma: A review of 509 cases. Bone Marrow Transpl 4:42-46, 1989 (suppl 4)
9. Philip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1037-1044, 1991
10. Kushner BH, O'Reilly RJ, Mandell LR, et al: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9:274-279, 1991
11. Kushner BH, Gulati SC, Kwon JH, et al: High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma. Cancer 68:242-247, 1991
12. Graham-Pole J, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9:152-158, 1991
13. Dini G, Lanino E, Garaventa D, et al: Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: Report of 34 cases. J Clin Oncol 9:962-969, 1991
14. Seeger RC, Villablanca JC, Matthay KK, et al: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma, in Evans AE, D'Angio GJ, Knudson AG, et al (eds): Advances in Neuroblastoma Research 3. New York, NY; Wylie/Liss, 1991, pp 527-533
15. Matthay KK, Atkinson JB, Stram DO, et al: Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Childrens Cancer Group pilot study. J Clin Oncol 11:2226-2233, 1993
16. Ladenstein R, Lasset C, Hartmann O, et al: Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: Report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 14:37-46, 1994
17. Evans AE, August CS, Kamani N, et al: Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: An update. Med Pediatr Oncol 23:323-327, 1994
18. Mugishima H, Iwata M, Okabe I, et al: Autologous bone marrow transplantation in children with advanced neuroblastoma. Cancer 74:972-977, 1994
19. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. Cancer 27:374-378, 1971
20. Brodeur G, Seeger RC, Barret A, et al: International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988
21. Shimada H, Chatten J, Newton J, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of gan-glioneuroblastoma and age-linked classification of neuroblastoma. J Natl Cancer Inst 73:405-416, 1984
22. Look AT, Hayes FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231-235, 1984
23. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 313:1111-1116, 1985
24. Hann HWL, Evans AE, Siegel SE, et al: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: the Children's Cancer Study Group experience. Cancer Res 45:2843-2848, 1985
25. Gansler T, Chatten J, Varello M, et al: How cytometric DNA analysis of neuroblastoma: Correlation with histology and clinical outcome. Cancer 58:2453-2458, 1986
26. Tsuchida Y, Honna T, Iwanaka T, et al: Serial determination of serum neuron-specific enolase in patients with neuroblastoma and other pediatric tumors. J Pediatr Surg 22:419-424, 1987
27. Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: A report from the Children's Cancer Study Group. Hum Pathol 19:1187-1198, 1988
28. Christiansen H, Lampert F: Tumor karyotype discriminates between god and bad prognostic outcome in neuroblastoma. Br J Cancer 57:121-126, 1988
29. Hsiao RJ, Seeger RC, Yu AL, et al: Chromogranin A in children with neuroblastoma: Serum concentration parallels disease stage and predicts survival. J Clin Invest 85:1555-1559, 1990
30. Valentino L, Moss T, Olson E, et al: Shed tumor gangliosides and progression of human neuroblastoma. Blood 75:1564-1567, 1990
31. Treleaven JG, Gibson FM, Ugelstad J, et al: Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1:70-73, 1984
32. Saarinen UM, Coccia PF, Gerson SL, et al: Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: Method for purging autologous bone marrow. Cancer Res 45:5969-5975, 1985
33. Kemshead JT, Heath L, Gibson FM, et al: Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: Experiences, improvements and observations. Br J Cancer 54:771-778, 1986
34. Reynolds CP, Seeger RC, Vo DD, et al: Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 46:5882-5886, 1986
35. Stein J, Strandjord S, Saarinen U, et al: In vitro treatment of autologous bone marrow for neuroblastoma patients with anti GD2 monoclonal antibody and human complement: A pilot study, in Evans AE, D'Angio GJ, Knudson AG, et al (eds.): Advances in Neuroblastoma Research 2. New York, NY, Alan R. Liss, 1988, pp 237-248
36. Cheung N-KV, Saarinen UM, Neely JE, et al: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649, 1985
37. Cheung N-KV, Saarinen UM, Neely JE, et al: Development of neuroblastoma monoclonal antibodies for potential utilization in diagnosis and therapy, in Evans AE, D'Angio GJ, Seeger RC (eds): Anvances in Neuroblastoma Research. New York, NY, Alan R. Liss, 1985, pp 501-505
38. Cheung N-KV, von Hoff DD, Strandjord SE, et al: Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 4:363-369, 1986
39. Saarinen UM, Sariola H, Hovi L: Recurrent disseminated retinoblastoma treated by high-dose chemotherapy, total body irradi- ation, and autologous bone marrow rescue. Am J Pediatr Hematol Oncol 13:315-319, 1991
40. Saarinen UM, Lähteenoja KM, Juvonen E: Bone marrow fractionation by the Haemonetics system: Reduction of the red cell mass before marrow freezing, with special reference to pediatric marrow volumes. Vox Sang 63:16-22, 1992
41. Guilbert LJ, Iscove NN: Partial replacement of serum by selenite, transferrin, albumin and lecithin in hematopoietic cell culture. Nature 263:594-595, 1976
42. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
43. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
44. Saarinen UM, Hovi L, Riikonen P, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia. Med Pediatr Oncol 20:489-496, 1992
45. Saarinen UM, Hovi L, Juvonen E, et al: Granulocyte colony-stimulating factor in allogeneic and autologous bone marrow transplantation in children. Med Pediatr Oncol 26:380-386, 1996
46. Favrot MC, Frappaz D, Maritaz O, et al: Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in the bone marrow. Br J Cancer 54:637-641, 1986
47. Rogers DW, Treleaven JG, Kemshead JT, et al: Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma. J Clin Pathol 42:422-426, 1989
48. Moss TJ, Reynolds P, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 324:219-226, 1991
49. Fisher B, Gunduz N, Saffer E: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43:1488-1492, 1983
50. Norton L: Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 12:231-249, 1985
51. Fidler U, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994
52. Graham-Pole J: The role of marrow autografting in neuroblastoma. Bone Marrow Transpl 4:3, 1989 (editorial)
53. Ohnuma N, Takahashi H, Kaneko M, et al: Treatment combined with bone marrow transplantation for advanced neuroblastoma: An analysis of patients who were pretreated intensively with the protocol of the study group of Japan. Med Pediatr Oncol 24:181-187, 1995
54. Moss TJ, Sanders DG, Lasky LC, et al: Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 76:1879-1883, 1990
55. Di Caro A, Bostrom B, Moss TJ, et al: Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma. Am J Pediatr Hematol Oncol 16:200-206, 1994